LUDWIG ENTERPRISES - LUDG STOCK NEWS

Ludwig Enterprises, Inc. (OTC PINK:LUDG) announced significant progress in its 2022 annual shareholder letter. Notable changes include the acquisition of mRNA genomic technology and the filing of a patent for the Precision Genomics MRNA Inflammatory Index. A new subsidiary, MyRNA for Life, Inc., was launched to market an antioxidant nutraceutical. Key achievements include onboarding to the SRAX Shareholder Platform, acquiring assets, and IPO preparations. These advancements aim to enhance early disease detection and offer substantial cost savings in healthcare.

Ludwig Enterprises, Inc. (OTC PINK:LUDG) has announced the acquisition of a nutraceutical formula from Xikoz, Inc., underlining their commitment to health innovation. The new product, MyRNA for Life, is scheduled for launch in Q1 2023 and focuses on modulating inflammatory conditions linked to chronic diseases such as cancer and diabetes. This acquisition aims to empower individuals in managing their health through nutrition while leveraging Ludwig's advanced genomics technology for early disease detection. The company is poised to impact the billion-dollar healthcare market significantly.

Ludwig Enterprises (OTC PINK: LUDG) is planning to up-list to NASDAQ following a form S-1 registration statement filing. The company aims for an IPO launch in Q1 2023, with $1 million bridge financing targeted, of which $500,000 has already been raised. The firm engaged Newlin Law Firm for the S-1 process, which includes a PCAOB audit. Additionally, Ludwig's subsidiary, Precision Genomics, has gained interest after a successful presentation at the LD Micro Conference. They focus on genetic biomarkers for chronic diseases.

Ludwig Enterprises (OTC PINK: LUDG) has announced significant advancements through its subsidiary, Precision Genomics, during a SEQUIRE Spotlight featuring Dr. Marvin S. Hausman M.D. Key developments include a recent patent filing for a diagnostic method targeting chronic inflammation, and an upcoming bladder cancer study. The company plans to file an S1 with the SEC to facilitate its uplisting to the NASDAQ. These efforts aim to enhance disease management and treatment options in the healthcare sector.

Ludwig Enterprises (OTC PINK:LUDG) announced a successful participation at the LD Micro Conference, showcasing its subsidiary, Precision Genomics. Dr. Marvin S. Hausman MD, recognized for his past successes in taking medical companies public, represented Precision Genomics and engaged in one-on-one meetings with major investment banks.

The company is preparing to file an S-1 with the SEC, aiming for a NASDAQ listing. Precision Genomics focuses on genomic testing to improve health outcomes, working on research related to Long Covid and other diseases.

Precision Genomics, a division of Ludwig Enterprises (OTC PINK:LUDG), reveals its proprietary mRNA technology aimed at diagnosing and treating Long Covid. This new approach utilizes a 48-gene mRNA microarray to provide a personalized inflammatory profile, potentially offering greater diagnostic accuracy compared to traditional blood tests. The company is preparing formal clinical trials for this technology while planning to file an S-1 with the SEC to achieve a NASDAQ listing. The market potential for this innovative diagnostic tool is significant, possibly reaching billions.

Ludwig Enterprises (OTC PINK:LUDG) announced advancements in its mRNA Inflammatory Index, a genetic tool designed to diagnose and manage chronic inflammatory diseases like heart disease and cancer. The company recently filed a crucial patent and is partnering with the Genetic Institute of America to leverage advanced robotic systems for mRNA testing. The global biochip market is projected to reach USD 34.35 billion by 2030, driven by the increasing prevalence of chronic diseases. CEO Anne Blackstone expressed optimism about the transformative potential of this technology.

Ludwig Enterprises announced the filing of a patent for its innovative mRNA Inflammatory Index™, a technology aimed at improving diagnosis and management of inflammatory diseases such as heart disease, diabetes, and various cancers. This patent covers proprietary methods for measuring genetic inflammatory biomarkers, potentially allowing early detection and treatment modification. The company highlights the untapped market for this technology within the billion-dollar healthcare sector, suggesting significant cost savings and improved patient outcomes. Market competition remains limited, presenting a unique opportunity.

Ludwig Enterprises has initiated discussions with Emerson Urology Associates to conduct a clinical study on bladder cancer patients' response to BCG immunotherapy. This collaboration aims to utilize Ludwig's proprietary genetic inflammatory biomarkers to create a predictive model for early-stage cancer diagnosis and treatment response. Ludwig's biomarker panel is currently being submitted for U.S. patent approval. With bladder cancer accounting for approximately 83,000 new cases annually in the U.S., this study could significantly impact treatment methodologies.